Nephropathy

(redirected from Diabetic nephropathy)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Diabetic nephropathy: diabetic retinopathy, diabetic neuropathy

nephropathy

[nə′fräp·ə·thē]
(medicine)
Any disease of the kidney.

Nephropathy

 

a general term that includes several renal disorders. Classified as nephropathies are nephropathy of pregnancy and a group of other kidney diseases that are distinguished from each other by a variety of morphological changes. This latter group of diseases includes myelogenous nephropathy, endemic, or Balkan, nephropathy, medicinally induced nephropathy, kaliopenic nephropathy, and hypercalcemic nephropathy.

REFERENCE

Osnovy nefrologii, vol. 2. Edited by E. M. Tareev. Moscow, 1972.
References in periodicals archive ?
In Europe, a rise in healthcare expenditure for diabetes treatment and increasing prevalence of diabetes in the various parts of Europe is boosting the growth of the European diabetic nephropathy market.
Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.
Another important concept in the pathogenesis of diabetic nephropathy is that hyperglycemia impairs autoregulation within the glomerulus by activating the local, intrarenal renin-angiotensin-aldosterone system, thus, compounding the hyperglycemia-induced injury.
While it reduces renal blood flow and glomerular filtration rate, it increases urinary protein excretion; the overall effect of exercise on diabetic nephropathy is controversial.
Patients with diabetic nephropathy had slightly lower mean hemoglobin levels prior to undergoing dialysis, compared with those who had nondiabetic renal disease (10.
Diabetic nephropathy is a common complication in type 1 and type 2 diabetes (20-40% incidence among diabetics) and is one of the leading causes of end-stage renal disease (ESRD) in the US.
Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
Spontaneous abortion rates in patients with HCG-positive pregnancy are 25% in the nondiabetic population and 32% in diabetic nephropathy patients with poor glycemic control.
Bristol-Myers Squib and Sanofi-Synthelabo report the FDA approval was based on results from an Irbesartan Diabetic Nephropathy Trial which demonstrated that when patients with high blood pressure, type 2 diabetes and evidence of kidney disease were treated with Avapro the risk of progression of their nephropathy or death was 20% lower than that of the placebo group and 23% lower than the group treated with amlodipine, a calcium-channel blocker.
said Tuesday its hypertension treatment drug Tanatril has been approved for treatment of diabetic nephropathy, a kidney abnormality.